Back to News
Market Impact: 0.4
Astra’s Experimental Stomach Cancer Drug Doubled Survival Time
Source: Bloomberg
Healthcare & BiotechCompany Fundamentals
AstraZeneca said its experimental stomach cancer drug doubled patient survival time in a late-stage trial, improving its prospects as a potential blockbuster. The article does not specify the survival period, trial results in detail, or any market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
AZN0.85
More News
- Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
- TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Here are 4 big things we're watching in the stock market this week
- SpaceX closes $40 billion debt deal for AI chips, Elon Musk says
- Earnings playbook: Alphabet, Microsoft, Amazon and more report this week. Here's what to expect
- More pain may be coming for the AI trade. Why I’m not giving up on it